MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00392-021-01970-4

Медицинская библиотека · Clinical research in cardiology : official journal of the German Cardiac Society · 2021

Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin.

Kaufmann Christoph C, Ahmed Amro, Kassem Mona, Freynhofer Matthias K, Jäger Bernhard, Aicher Gabriele, Equiluz-Bruck Susanne, Spiel Alexander O, Vafai-Tabrizi Florian, Gschwantler Michael, Fasching Peter, Wojta Johann, Giannitsis Evangelos, Huber Kurt

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease.

METHODS

This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from June 6th to November 26th, 2020 in a tertiary care hospital. Copeptin and high-sensitive cardiac troponin I (hs-cTnI) levels on admission were collected and tested for their association with the primary composite endpoint of ICU admission or 28-day mortality.

RESULTS

A total of 213 eligible patients with COVID-19 were included of whom 55 (25.8%) reached the primary endpoint. Median levels of copeptin and hs-cTnI at admission were significantly higher in patients with an adverse outcome (Copeptin 29.6 pmol/L, [IQR, 16.2-77.8] vs 17.2 pmol/L [IQR, 7.4-41.0] and hs-cTnI 22.8 ng/L [IQR, 11.5-97.5] vs 10.2 ng/L [5.5-23.1], P < 0.001 respectively). ROC analysis demonstrated an optimal cut-off of 19.3 pmol/L for copeptin and 16.8 ng/L for hs-cTnI and an increase of either biomarker was significantly associated with the primary endpoint. The combination of raised hs-cTnI and copeptin yielded a superior prognostic value to individual measurement of biomarkers and was a strong prognostic marker upon multivariable logistic regression analysis (OR 4.274 [95% CI, 1.995-9.154], P < 0.001). Addition of copeptin and hs-cTnI to established risk models improved C-statistics and net reclassification indices.

CONCLUSION

The combination of raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized patients with COVID-19.

Для цитирования: Kaufmann Christoph C, Ahmed Amro, Kassem Mona, Freynhofer Matthias K, Jäger Bernhard, Aicher Gabriele, Equiluz-Bruck Susanne, Spiel Alexander O, Vafai-Tabrizi Florian, Gschwantler Michael, Fasching Peter, Wojta Johann, Giannitsis Evangelos, Huber Kurt. Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin.. Clinical research in cardiology : official journal of the German Cardiac Society. 2021. DOI: 10.1007/s00392-021-01970-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.